Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
98 results about "Endocrine therapy" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Endocrine therapy is a critical part of adjuvant therapy in women with hormone receptor–positive breast cancer, and has been shown to reduce the risk of recurrence and death from breast cancer.
Foamable compositions, kits and methods for hyperhidrosis
ActiveUS20070253911A1Ameliorating and reducing perspirationExcessive hyperhidrosisCosmetic preparationsBiocideDiseasePlantar hyperhidrosis
The composition of the present invention is geared towards treating hyperhidrosis or any condition involving and / or promoting excessive sweating, typically involving the whole body, include hyperthyroidism or similar endocrine disorders; endocrine treatment for prostatic cancer or other types of malignant disorder; severe psychiatric disorders; obesity and menopause. The foamable composition of the present invention is suitable for treating palmar hyperhidrosis; axillary hyperhidrosis; plantar hyperhidrosis; hyperhidrosis of the trunk and / or the thighs; and facial hyperhidrosis; and any combination of them consisting of a therapeutic foamable composition including: an active agent, suitable for the treatment or prevention of hyperhidrosis.
Owner:VYNE THERAPEUTICS INC
Foamable Compositions, Kits and Methods for Hyperhidrosis
The composition of the present invention is geared towards treating hyperhidrosis or any condition involving and / or promoting excessive sweating, typically involving the whole body, include hyperthyroidism or similar endocrine disorders; endocrine treatment for prostatic cancer or other types of malignant disorder; severe psychiatric disorders; obesity and menopause. The foamable composition of the present invention is suitable for treating palmar hyperhidrosis; axillary hyperhidrosis; plantar hyperhidrosis; hyperhidrosis of the trunk and / or the thighs; and facial hyperhidrosis; and any combination of them consisting of a therapeutic foamable composition including: an active agent, suitable for the treatment or prevention of hyperhidrosis.
Owner:FOAMIX PHARMACEUTICALS LIMITED
Foamable compositions, kits and methods for hyperhidrosis
The composition of the present invention is geared towards treating hyperhidrosis or any condition involving and / or promoting excessive sweating, typically involving the whole body, include hyperthyroidism or similar endocrine disorders; endocrine treatment for prostatic cancer or other types of malignant disorder; severe psychiatric disorders; obesity and menopause. The foamable composition of the present invention is suitable for treating palmar hyperhidrosis; axillary hyperhidrosis; plantar hyperhidrosis; hyperhidrosis of the trunk and / or the thighs; and facial hyperhidrosis; and any combination of them consisting of a therapeutic foamable composition including: an active agent, suitable for the treatment or prevention of hyperhidrosis.
Owner:VYNE THERAPEUTICS INC
Foamable compositions and methods for disorders of the skin or mucosal surfaces
The composition of the present invention is geared towards treating hyperhidrosis or any condition involving and / or promoting excessive sweating, typically involving the whole body, include hyperthyroidism or similar endocrine disorders; endocrine treatment for prostatic cancer or other types of malignant disorder; severe psychiatric disorders; obesity and menopause. The foamable composition of the present invention is suitable for treating palmar hyperhidrosis; axillary hyperhidrosis; plantar hyperhidrosis; hyperhidrosis of the trunk and / or the thighs; and facial hyperhidrosis; and any combination of them consisting of a therapeutic foamable composition including: an active agent, suitable for the treatment or prevention of hyperhidrosis.
Owner:FOAMIX PHARMACEUTICALS LIMITED
Antisense insulin-like growth factor binding protein (IGFBP)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapy
InactiveUS7196067B2Reduce spreadDelay progression to androgen independenceSugar derivativesPeptide/protein ingredientsMammalAntisense oligodeoxynucleotides
Compositions and a method are provided for the treatment of prostate and other endocrine tumors in mammals, including humans, by administration of an antisense oligodeoxynucleotide (ODN) which is complementary to a portion of the gene encoding IGFBP-2. Using the Shionogi tumor model in vitro and in vivo, the administration of such an ODN was shown to reduce proliferation of tumor cells, and also to delay the progression to androgen independence. Thus, treatment of prostate and other hormone-regulated cancer in mammals, including humans, and delay of the progression of prostate tumors to androgen independence is accomplished by administering to the mammal a therapeutically effective amount of an antisense oligodeoxynucleotide which is complementary to a portion of the nucleic acid sequence encoding IGFBP-2 and which reduces the amount of IGFBP-2 in the treated cells.
Owner:THE UNIV OF BRITISH COLUMBIA
Post-treatment breast cancer prognosis
InactiveUS20130281502A1Accurate assessmentBiocideMicrobiological testing/measurementInitial treatmentCancer metastasis
The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to extended treatment and cancer-free survival in a patient. In particular, the disclosure includes the identities of genes that are expressed in correlation with benefit in a switch in endocrine therapy used to treat a patient. The levels of gene expression are disclosed as a molecular index for predicting clinical outcome, and so prognosis, for the patient. The disclosure further includes methods for predicting cancer recurrence, and / or predicting occurrence of metastatic cancer, after initial treatment with an anti-estrogen agent. The disclosure further includes methods for determining or selecting the treatment of a subject based upon the likelihood of life expectancy, cancer recurrence, and / or cancer metastasis.
Owner:THE GENERAL HOSPITAL CORP +1
Method for breast cancer recurrence prediction under endocrine treatment
InactiveUS20130065786A1Reliable predictionNucleotide librariesMicrobiological testing/measurementDisease outcomeEndocrine therapy
The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising:(a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP(b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.
Owner:SIVIDON DIAGNOSTICS
Combined application of isothiocyanate compound and anti-cancer medicine
ActiveUS10010520B2Good treatment effectHeavy metal active ingredientsNervous disorderEndocrine therapyCancer cell
The present invention relates to a combined application of isothiocyanate compounds and anti-cancer drugs, in particular to a composition, comprising: (A) a therapeutically effective amount of a first active ingredient, the first active ingredient being an isothiocyanate compound or derivative thereof; (B) a therapeutically effective amount of a second active ingredient, the second active ingredient being anti-cancer drugs effecting or influencing DNA, kinase inhibitor anti-cancer drugs or endocrine therapy hormonal anti-cancer drugs, the mass ratio of the first active ingredient and the second active ingredient being from 1:10000 to 10000:1. Also disclosed are an active ingredient composition, kit, pharmaceutical composition and uses thereof in the preparation of anti-cancer drugs. The composition, active ingredient composition and kit have excellent effect of inhibiting the growth of cancer cells.
Owner:JC (WUXI) CO INC
MN/CA IX and Breast Cancer Therapy
InactiveUS20090047215A1Improve the immunityOrganic active ingredientsBiocideAbnormal tissue growthAntigen
Herein disclosed are methods that are predictive of resistance to endocrine therapy in an estrogen receptor-positive (ER-positive) breast cancer patient. An exemplary method comprises detecting the overexpression of MN / CA9 gene expression product(s) in a sample from an affected subject, wherein if MN / CA9 is overexpressed, then the subject is considered to have a greater probability of resistance to endocrine therapy, particularly tamoxifen, and a corresponding poorer prognosis if undergoing endocrine therapy, than if MN / CA9 is not overexpressed. MN / CA9 gene expression products useful in the predictive / prognostic methods include MN / CA IX, MN proteins / polypeptides, MN nucleic acids and soluble MN / CA IX antigen (s-CA IX). The methods are useful as an aid in the selection of treatment for a patient with an ER-positive breast tumor. The methods of the invention can be used, for example, to identify those patients requiring additional / alternative therapies, preferably, but not necessarily, therapies that are not affected by acidic pH. The methods also comprise the use of diagnostic / prognostic imaging to detect MN / CA IX in a patient tumor, wherein the presence of MN / CA IX in one or more tumors is indicative of probable resistance to antiestrogen therapy, particularly to tamoxifen.
Owner:BIOMEDICAL RES CENT OF THE SLOVAK ACADEMY OF SCI
Topical formulations of 5-alpha-reductase inhibitors and uses thereof
ActiveUS20200147071A1Increase in hair countExpand coverageCosmetic preparationsOrganic active ingredientsSide effectBULK ACTIVE INGREDIENT
Disclosed herein are topical compositions of 5-α reductase inhibitors, such as dutasteride or finasteride, or a pharmaceutically acceptable salt, ester, or derivative thereof and the use of the compositions for the treatment of hair loss secondary to endocrine therapy in patients with breast cancer (Endocrine Therapy-Induced Alopecia or ETIA), androgenetic alopecia (AGA), alopecia areata, and hirsutism. The topical composition is advantageous over the existing oral compositions of 5-α reductase inhibitors because the topical composition is safer and more effective. The topical formulation may allow for a slow release of the active ingredient dutasteride, better penetration at the therapeutically effective amount of dutasteride with an improved safety profile because it does not need to travel through the bloodstream to be efficacious, thereby minimizing the risk of systemic side effects.
Owner:VARSONA THERAPEUTICS INC
Inhibition of autophagy genes in cancer chemotherapy
InactiveUS20100129429A1High selectivityReduce non-specificityOrganic active ingredientsSugar derivativesEndocrine therapyRadical radiotherapy
Owner:BRITISH COLUMBIA CANCER AGENCY
A medicinal preparation for treating breast cancer and preparation method thereof
Owner:SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M
Detection of steroid receptors on circulating carcinoma cells and treatment
The expression of a steroid receptor from circulating carcinoma cells in a blood sample is detected by isolating the carcinoma cells from the blood sample, making an extract from the isolated carcinoma cells and then performing on the extract a sensitive immunoassay capable of detecting the carcinoma cell-associated steroid receptor. A positive result indicates the presence of the steroid receptor in the carcinoma cells. This method can be used to identify cancer patients who are likely to benefit from treatment with an endocrine therapeutic agent.
Owner:WELLSTAT BIOLOGICS CORP
Method for breast cancer recurrence prediction under endocrine treatment
ActiveUS20170067118A1Reliable predictionMicrobiological testing/measurementMaterial analysisDisease outcomeEndocrine therapy
The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising:(a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP(b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.
Owner:SIVIDON DIAGNOSTICS
Predicting likelihood of response to combination therapy
Provided are methods of determining whether a subject having ER+ breast cancer is expected to benefit from treatment with combination endocrine therapy and mTOR inhibitor therapy. Also provided are methods of treating a subject having ER+ breast cancer.
Owner:BIOTHERANOSTICS
Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
InactiveUS7238674B2Efficient deliverySustained productionBiocidePeptide/protein ingredientsMuscle tissueHigh level expression
The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.
Owner:GENZYME CORP +1
Methods of treating pr-positive, luminal a breast cancer with pi3k inhibitor, pictilisib
InactiveUS20150335650A1Organic active ingredientsMicrobiological testing/measurementEndocrine therapyPictilisib
Methods and compositions are provided for treating breast cancer in patients with a PI3K inhibitor, GDC-0941 in combination with an endocrine therapy agent.
Owner:GENENTECH INC
Markers for identifying breast cancer treatment modalities
InactiveUS20140011695A1Microbiological testing/measurementLibrary screeningEndocrine therapyOncology
The present invention includes methods for identifying patients who will be resistant to endocrine therapy during breast cancer treatment and determining patient outcome. The methods are based on identifying increased expression of PBX1, or the cistrome signature associated therewith, in breast tissue samples.
Owner:TRUSTEES OF DARTMOUTH COLLEGE THE
Activators of the unfolded protein response
ActiveUS20200190029A1Increase lethalityIncreased therapeutic potentialOrganic active ingredientsOrganic chemistry methodsCancer cellOncology
A set of small molecules ERα biomodulators that kill therapy-resistant ERα positive breast, ovarian, and endometrial cancer cells. These small molecules have increased therapeutic potential because of an increased ability to kill therapy-resistant breast cancer cells compared to BHPI and other conventional therapies (endocrine therapies, tamoxifen and fulvestrant / ICI). The new compounds do not only inhibit proliferation of the cancer cells but actually kills them, which prevents reactivation of tumors years later.
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS
Novel Androgen Effectors
ActiveUS20170151271A1Sugar derivativesHydroxy compound active ingredients5 Alpha-Reductase InhibitorEndocrine therapy
The invention discloses novel endocrine treatment phytochemicals which affect androgenic status. The method for treatment of 5-alpha-reductase responsive diseases using four novel 5-alpha-reductase inhibitor compounds; leucoanthocyanidin, glabrene, glabridin, and alpha-terpineol is disclosed. Glabridin does not interfere with normal testosterone to androgen receptor binding.
Owner:PAXTON PIERSON SUZANNE J
Establishing method for rabbit tongue carcinoma model
InactiveCN105580774AHigh cure rateImprove survival rateAnimal husbandryAbnormal tissue growthTongue Carcinoma
The invention provides an establishing method for a rabbit tongue carcinoma model. The method comprises the following steps: establishing rabbit tongue squamous carcinoma cell lines; inoculating the rabbit tongue squamous carcinoma cells under skin of a nude mouse and culturing the nude mouse; taking cultured nude mouse subcutaneous tumor tissue, and inoculating the subcutaneous tumor tissue on a rabbit tongue, to establish a rabbit tongue carcinoma model; based on the rabbit tongue carcinoma model, establishing a high lymph gland metastatic rabbit tongue carcinoma animal model. Establishing a tongue carcinoma animal model with high lymph gland metastatic potential completely re-represents clinical characteristics of tongue carcinoma and lymphatic metastasis biological characteristics, and provides better experimental basis for prevention and treatment of tongue carcinoma. The method can be used for sensitivity evaluation of anti-tumor chemotherapeutics, and can also be used for research of radiotherapy, endocrinotherapy, immunological therapy, molecular targeting treatment, and other new treatment means.
Owner:SHANGHAI NINTH PEOPLES HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Long non-coding RNA BDNF-AS and application thereof as marker and therapeutic target
InactiveCN113201534AEfficient screeningImprove accuracyOrganic active ingredientsMicrobiological testing/measurementSide effectTreatment targets
The invention relates to a long non-coding RNA BDNF-AS and application thereof in preparing a product for diagnosing tumors or judging prognosis conditions of breast cancer treatment or judging drug resistance of breast cancer endocrine treatment or treating tumors. The BDNF-AS is taken as a marker, whether breast cancer cells in a sample are resistant to drugs and the prognosis condition of breast cancer can be judged by detecting the expression level of the BDNF-AS in the sample, so that a more effective treatment method is implemented based on a judgment result, the treatment effect is improved, and more side effects caused by blind dosage are avoided. Meanwhile, the long non-coding RNA BDNF-AS can also be used as a treatment target, and the sensitivity of endocrine treatment of the drug-resistant breast cancer to an endocrine treatment drug can be improved by knocking down the BDNF-AS, so that the treatment effect of the drug is improved; the tumor growth can be directly inhibited by singly knocking down the BDNF-AS, so that the BDNF-AS can be combined with other endocrine treatment medicines to realize a synergistic treatment effect.
Owner:SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV
Method for predicting response to endocrine therapy
The present invention relates to a method for predicting the response of a patient diagnosed with breast cancer to treatment with an endocrine therapy drug, comprising the steps of: (a) measuring the binding of the estrogen receptor, obtained from a breast cancer tumor from said patient, generating a binding profile, said binding profile comprising the binding of the estrogen receptor from said patient on one or more co-regulator proteins or functional parts thereof in the presence and absence of one or more added phosphatases, (b) measuring the binding of the estrogen receptor, obtained from a breast cancer tumor from said patient, generating a binding profile, said binding profile comprising the binding of the estrogen receptor from said patient on one or more co-regulator proteins or functional parts thereof in the presence and absence of added estradiol, and, (c) predicting from said binding profiles the response of said patient to endocrine drug therapy. The present invention also relates to variant methods hereof and methods for predicting the response of a patient diagnosed with breast cancer to drug treatment and methods for individualized endocrine therapy of a patient diagnosed with an endocrine related disease. The invention also relates to arrays and kits for carrying out these methods.
Owner:NETHERLANDS CANCER INST +1
Topical dutasteride emulsions for treating endocrine therapy-induced alopecia
ActiveUS20210353643A1Ameliorate hair lossAmeliorating hair lossOrganic active ingredientsOintment deliveryEndocrine therapyHair loss
The invention features topical dutasteride emulsions for local delivery to the dermis of a subject suffering from hair loss, such as hair loss secondary to endocrine therapy in patients with breast cancer.
Owner:VARSONA THERAPEUTICS INC
Proteolytic targeted chimeric compound taking oxygen bridge bicycloheptene compound as estrogen receptor ligand as well as preparation method and application
The invention discloses a proteolytic targeted chimeric compound taking an oxygen bridge bicycloheptene compound as an estrogen receptor ligand as well as a preparation method and an application. Tworeasonable synthesis modes are adopted, a VHL ligand or a CRBN ligand serves as an E3 ligase ligand part, oxygen bridge bicycloheptene sulfonate or sulfonamide estrogen receptor ligands are connectedthrough alkyl side chains with different lengths, and a series of target product Protac molecules are obtained through synthesis. An action mode of the Protac molecules is different from that of an existing anti-breast cancer drug tamoxifen, and the Protac molecules are targeted estrogen down-regulators. The compound not only retains a certain estrogen receptor binding capacity, but also has goodestrogen receptor alpha down-regulation activity equivalent to that of fulvestrant, can realize event-driven targeted estrogen receptor degradation, and is expected to overcome drug resistance causedby traditional endocrine treatment of the ER positive breast cancer through the method.
Owner:WUHAN UNIV
Methods for delivering DNA to muscle cells using recombinant adeno-associated virus virions vectors
InactiveUS20080069803A1Efficient deliverySustained productionBiocidePeptide/protein ingredientsMuscle tissueHigh level expression
Owner:GENZYME CORP
Transcriptomic profiling for prognosis of breast cancer
PendingCN113557310AMechanical/radiation/invasive therapiesHealth-index calculationEndocrine therapyBiologic marker
Methods, systems, and kits for the diagnosis, prognosis, and treatment of breast cancer in a subject are disclosed. The invention also provides biomarkers and clinically useful classifiers for identifying subjects at low risk of breast cancer recurrence who may be spared from adjuvant chemotherapy and endocrine therapy. Further disclosed herein, in certain instances, are probe sets for use in detecting such biomarkers for determining the risk of breast cancer recurrence in a subject. Methods of beating breast cancer based on expression profiling to determine the risk of breast cancer recurrence are also provided.
Owner:PFS GENOMICS INC +1
Method for targeted inhibition of infiltration and transfer of glioma cells and application of method
InactiveCN102643785AOvercoming non-selectivityImproved prognosisGenetic material ingredientsAntibody ingredientsCell adhesionIn vivo
The invention discloses a method for targeted inhibition of infiltration and transfer of glioma cells, which includes targeted inhibition of JAM2 (junctional adhesion molecules 2) of the glioma cells. Experiments show that cell proliferative activity of the glioma cells can be inhibited in vivo by 30% by inhibition on the JAM2 of the glioma cells, cell migration activity can be inhibited by more than 80%. The method has superb clinical application prospect, and by the method, non-specificity of existing drug therapy on glioma cell cases, the defects in surgical therapy, radiotherapy, chemotherapy and endocrine therapy are overcome, and the range of targeted therapy is widened.
Owner:ZHEJIANG FOCUSGEN BIOENG
Molecular marker cuedc2 protein for prognostic determination of breast cancer endocrinology therapy
ActiveUS20140066604A1Improve accuracyGood treatment effectSugar derivativesImmunoglobulins against animals/humansSurgical operationRegimen
Disclosed is a use of the CUEDC2 protein in the preparation of diagnostic agents for prognostic determination of the endocrinology therapy for the breast cancer patients and for the diagnosis of tumor such as breast cancer and ovarian cancer. The diagnostic agent comprises an antibody against the CUEDC2 protein, wherein the antibody is a monoclonal or polyclonal antibody against the CUEDC2 protein. Provided is a kit or a composition for prognostic determination of endocrinology therapy for the breast cancer patients and for the diagnosis of tumors such as breast cancer and ovarian cancer. The kit or composition comprises an antibody against the CUEDC2 protein. Further disclosed is a use of the CUEDC2 gene or protein in preparation of drugs for treating tumors, that is, small molecular substances and specific antibodies that specifically inhibit the expression or activity of the CUEDC2 gene\protein are used as a therapeutic agent to restore the sensitivity of drug-resistant tumors to drug treatment. The new use of the CUEDC2 protein provides a new basis for determining a dosage regimen of adjuvant therapy after surgical operation of the breast cancer patients, thereby improving the therapeutic effect of the anti-cancer drugs and alleviating the suffering and economic burden of the patients.
Owner:BIOMEDICAL ANALYSIS CENT OF ACADEMY OF MILITARY MEDICAL SCI
Targeting breast cancer therapy based on stromal subtypes and cd146 composition
ActiveUS20170269088A1Facilitated DiffusionOrganic active ingredientsMicrobiological testing/measurementFhit geneWilms' tumor
Methods for targeted breast cancer therapy in a subject based upon evaluating the stromal subtypes and CD146 composition in the adjacent tissue. ER+ breast cancers contain two CAF subtypes defined by CD146 expression. CD146neg CAFs suppress ER expression in ER+ breast cancer cells, decrease tumor cell sensitivity to estrogen, switch ER proliferation dependency toward EGFR dependency and decrease tumor cell sensitivity to antiendocrine therapy. Conversely, the presence of CD146Ppos CAFs enhances ER expression in ER+ breast cancer cells and sustains ER-dependent proliferation and sensitivity to tamoxifen. Co-cultures of CD146pos CAFs with tamoxifen-resistant breast cancer cells restores sensitivity to tamoxifen. Gene expression profiles of patient breast tumors with predominantly CD146neg CAFs correlate with inferior clinical response to tamoxifen and worse patient outcomes. CAF composition contributes to treatment response and patient outcomes in ER+ breast cancer, and provide a target for drug development.
Owner:UNIV OF COLORADO THE REGENTS OF
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com